Modeling efficacy of bevacizumab treatment for metastatic colon cancer

Journal of Cancer

Volumn 4, Issue 4, 2013, Pages 330-335

  Islam, Rezwan ^a   Chyou, Po Huang ^a   Burmester, James K ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

Bevacizumab; Colon cancer; Monoclonal antibodies; Prognosis; Vascular endothelial growth factor VEGF

Indexed keywords

BEVACIZUMAB;

ARTICLE; ASCENDING COLON; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SCREENING; CECUM; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CANCER; DRUG EFFICACY; FECES; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; PRIMARY TUMOR; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84883035530     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.6083     Document Type: Article

References (18)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011. CA Cancer J Clin. 2011; 61:212-236.
2. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006; 28:1779-1802.
3. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25
4. Selvakumaran M, Yao KS, Feldman MD, et al Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol. 2008;75:627-638
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med. 2004;350:2335-2342
6. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Onc. 2005;23:3502-3508
7. McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68:487-506
8. Golfinopoulos V, Salanti G, Pavlidis N, et al. Survival and dis-ease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol. 2007;8:898-911
9. Higa GM, Abraham J. Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther. 2009;9:999-1007
10. Tappenden P, Jones R, Paisley S, et al. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer. 2007;43:2487-2494.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
12. Tuma RS. Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Nat Cancer Inst. 2006;98:1272-1274.
13. Hong YS, Cho HJ, Kim SY, et al. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer. 2009;9:246-254.
14. Guiu B, Petit JM, Bonnetain F, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab based treatment in metastatic colorectal cancer. Gut. 2010;59:341-347.
15. Ryanne Wu R, Lindenberg PA, Slack R, et al. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer. 2009; 40:101-108.
16. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor- 2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;28:4672-4678.
17. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981-989.
18. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospoindin-2 expression, and mi-cro-vessel density on the treatment effect of bevacizuamab in metastatic colorectal cancer. J Clin Oncol. 2006;24:217-227.